Pages that link to "Q40498632"
Jump to navigation
Jump to search
The following pages link to Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. (Q40498632):
Displaying 50 items.
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents (Q21198868) (← links)
- Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress (Q23918915) (← links)
- Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia (Q26771790) (← links)
- Trials with 'epigenetic' drugs: an update (Q27000542) (← links)
- Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion (Q28284160) (← links)
- PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy (Q28388468) (← links)
- Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment (Q28482066) (← links)
- Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer (Q28538435) (← links)
- Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch (Q28828176) (← links)
- Anticancer activities of histone deacetylase inhibitors (Q29616624) (← links)
- DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. (Q30931932) (← links)
- First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors (Q33410544) (← links)
- Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML) (Q34082540) (← links)
- The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells (Q34176804) (← links)
- Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation (Q34267286) (← links)
- Ubiquitination-dependent regulation of signaling receptors in cancer (Q34365210) (← links)
- Epigenetic drugs against cancer: an evolving landscape (Q34431964) (← links)
- Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia (Q34493326) (← links)
- Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha (Q34519869) (← links)
- The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). (Q34725589) (← links)
- Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic (Q34817365) (← links)
- LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway (Q34952741) (← links)
- T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells (Q35048659) (← links)
- Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia (Q35125923) (← links)
- Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. (Q35127277) (← links)
- Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia (Q35176062) (← links)
- Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells (Q35685058) (← links)
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias (Q35750919) (← links)
- Heat shock protein 90 inhibition in lung cancer (Q35762499) (← links)
- Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment (Q35800838) (← links)
- Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs (Q35823157) (← links)
- The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells (Q35870933) (← links)
- Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. (Q35900937) (← links)
- Efficacy of vorinostat in a murine model of polycythemia vera (Q35909673) (← links)
- Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells (Q35990736) (← links)
- The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy (Q36087855) (← links)
- Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach (Q36177918) (← links)
- Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up? (Q36187025) (← links)
- Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia (Q36242646) (← links)
- Signal transduction of oncogenic Flt3. (Q36251180) (← links)
- FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis (Q36334327) (← links)
- Targeting chaperones in transformed systems--a focus on Hsp90 and cancer (Q36379365) (← links)
- Identifying drug-pathway association pairs based on L1L2,1-integrative penalized matrix decomposition (Q36408203) (← links)
- Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond (Q36429460) (← links)
- Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. (Q36461618) (← links)
- Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells (Q36539785) (← links)
- Inhibitors of the HSP90 molecular chaperone: current status (Q36543819) (← links)
- Assays for pharmacodynamic analysis of histone deacetylase inhibitors (Q36546255) (← links)
- An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain (Q36566693) (← links)
- Inhibitors of signal transduction protein kinases as targets for cancer therapy (Q36625236) (← links)